HIV-1 Integrase Inhibitor Resistance by Sequencing (INACTIVE as of 08/16/21: Refer to 3003853 with the August Hotline)
HIV genotyping provides susceptibility information for integrase inhibitors (INI). Intended for patients with viral load >500 copies/mL.
Reverse Transcription Polymerase Chain Reaction/Sequencing
New York DOH Approval Status
Lavender (EDTA), pink (K2EDTA), or plasma preparation tube.
Separate plasma from cells within 6 hours. Transfer 4 mL plasma to an ARUP Standard Transport Tube. (Min: 1.5 mL)
Serum. Heparinized specimens.
Please submit most recent viral load and test date, if available.
On cells: Ambient: 6 hours; After separation from cells: Ambient: 24 hours; Refrigerated: 5 days; Frozen: 4 months
The entire integrase-encoding region is sequenced. Mutations associated with resistance to integrase inhibitors are reported. Mutations in viral sub-populations below 20 percent of total may not be detected.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
This test may be unsuccessful if the plasma HIV-1 RNA viral load is less than 500 HIV-1 RNA copies per mL of plasma.
|Component Test Code*||Component Chart Name||LOINC|
|2004458||HIV-1 Integrase Inhib. Resistance, Seq||72560-6|
- HIV Drug Resistance
- HIV Integrase Genotype
- HIV Integrase Inhibitor Resistance
- HIV Treatment Susceptibility Testing
- HIV1 Integrase Resistance
- HIV1 Integrase Sequencing
- HIV1 Sequencing
- Raltegravir (Isentress(TM)) Resistance